Overview

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Status:
Terminated

Trial end date:
2020-07-29

Target enrollment:

Participant gender:

Summary

Dabrafenib and trametinib are drugs that are usually given for the treatment of melanoma. Combinations of dabrafenib and trametinib have also been studied and when used together have shown to increase tumour shrinkage in animals compared to either drug alone. Dabrafenib and trametinib have also shown potential to penetrate the blood-brain-barrier when given together and have an effect on brain metastases. Giving these drugs at the same time and then giving brain stereotactic radiosurgery (SRS) may also be preferred in patients with brain metastases

Phase:

Phase 2

Details

Lead Sponsor:

Canadian Cancer Trials Group

Collaborator:

Novartis

Treatments:

Dabrafenib
Trametinib